Dongwha Pharm Co Ltd
000020
Company Profile
Business description
Dongwha Pharm Co Ltd is engaged in manufacturing and selling pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/ respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system among several other products.
Contact
5 Soon wha-Dong
Jung-gu
Seoul
KORT: +82 220219300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
846
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,515.81 | 30.17 | 0.36% |
| DAX 40 | 25,580.34 | 31.69 | -0.12% |
| Dow JONES (US) | 52,244.70 | 36.64 | 0.07% |
| FTSE 100 | 10,872.38 | 24.89 | -0.23% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,200.19 | 78.01 | 0.31% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,443.34 | 5.71 | 0.08% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |